MRK vs UTHR
Merck & Co. vs United Therapeutics — AI-powered side-by-side comparison
VS
UTHR
United Therapeutics
72
Buy
| Metric | MRK | UTHR |
|---|
| AI Score |
70
|
72
|
| Price |
$130.34
|
$514.89
|
| P/E Ratio |
103.53×
|
17.05×
|
| ROE |
34.7%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
86.1%
|
| Debt / Equity |
1.29×
|
0.00×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
52.2
|
| Beta |
0.207
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for MRK versus UTHR.
UTHR leads by 2 points.
UTHR scores 72/100 (Buy) versus MRK at 70/100 (Buy).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.